Nevirapine
- Generic Name
- Nevirapine
- Brand Names
- Viramune
- Drug Type
- Small Molecule
- Chemical Formula
- C15H14N4O
- CAS Number
- 129618-40-2
- Unique Ingredient Identifier
- 99DK7FVK1H
- Background
A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
- Indication
For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Changing to Nonprotease Inhibitor Treatment to Improve Side Effects
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-02-28
- Target Recruit Count
- 342
- Registration Number
- NCT00021463
- Locations
- 🇺🇸
Northwestern Univ Med School, Chicago, Illinois, United States
🇺🇸Univ of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Emory Univ, Atlanta, Georgia, United States
An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT00002194
- Locations
- 🇺🇸
South Florida Bioavailability Clinic, Miami, Florida, United States
A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2014-04-17
- Target Recruit Count
- 1710
- Registration Number
- NCT00000922
- Locations
- 🇺🇸
Louisiana Comm AIDS Rsch Prog / Tulane Univ Med, New Orleans, Louisiana, United States
🇺🇸Washington Reg AIDS Prog / Dept of Infect Dis, Washington, District of Columbia, United States
🇺🇸Harlem AIDS Treatment Grp / Harlem Hosp Ctr, New York, New York, United States
Effectiveness of AZT and Nevirapine in Preventing HIV Transmission From Ugandan Mothers to Their Newborns
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 1500
- Registration Number
- NCT00006396
- Locations
- 🇺🇸
Missie Allen, Research Triangle Park, North Carolina, United States
A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 49
- Registration Number
- NCT00000808
- Locations
- 🇺🇸
Univ of Connecticut / Farmington, Farmington, Connecticut, United States
🇺🇸Univ of Massachusetts Med School, Worcester, Massachusetts, United States
🇺🇸Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States
A Study to Compare Two Different Anti-HIV Drug Regimens
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 120
- Registration Number
- NCT00000924
- Locations
- 🇺🇸
Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States
🇺🇸Cook County Hosp, Chicago, Illinois, United States
🇺🇸Chicago Children's Memorial Hosp, Chicago, Illinois, United States
A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their Babies
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 1244
- Registration Number
- NCT00000942
- Locations
- 🇮🇹
Universita Frederico II, Napoli, Italy
🇧🇸Princess Margaret Hosp, Nassau, Bahamas
🇫🇷CHRU de Nantes, Nantes, France
Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 55
- Registration Number
- NCT00004855
- Locations
- 🇺🇸
Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸Denver Dept of Health and Hosps, Denver, Colorado, United States
🇺🇸Northwestern Univ Med School, Chicago, Illinois, United States
A Study of Nevirapine for the Prevention of HIV Transmission From Mothers to Their Babies
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 2009
- Registration Number
- NCT00000869
- Locations
- 🇺🇸
Univ of South Alabama, Mobile, Alabama, United States
🇺🇸UCSD Med Ctr / Pediatrics / Clinical Sciences, La Jolla, California, United States
🇺🇸UCLA Med Ctr / Pediatric, Los Angeles, California, United States
The Safety of Nevirapine When Given to Breast-Feeding Babies From Birth to Age 6 Months
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 75
- Registration Number
- NCT00006279
- Locations
- 🇺🇸
Kathy George, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.